CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2018-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the following investor conferences:

• the BIO CEO & Investor Conference on Monday, February 12, 2018, at 2:15 p.m. Eastern Time, at the New York Marriott Marquis in New York, NY; and
• the RBC Capital Markets 2018 Global Healthcare Conference on Thursday, February 22, 2018, at 8:00 a.m. Eastern Time at the Lotte New York Palace in New York, NY.

A live webcast of the presentations will be available on the company’s website at www.akebia.com. To access the webcast, please log onto the Akebia website at least 15 minutes prior to the webcast to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia’s website following the conferences.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180208005168/en/

Source: Akebia Therapeutics, Inc.

Akebia Therapeutics
John Garabo, 617-844-6130
Director, Corporate Communications
jgarabo@akebia.com